comparemela.com

Latest Breaking News On - Laurie hurst - Page 5 : comparemela.com

PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma - News Makers

PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma Pharmaceutical, biotech and other research sponsors can now connect their clinical studies to longitudinal real-world data – speeding up drug development and aligning with the 21st Century Cures Act. RALEIGH, N.C., May 13, 2021 (GLOBE NEWSWIRE) PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today an innovative tokenization solution using Synoma ®, PRA’s proprietary technology that allows for the generation of enhanced evidence for drug development. PRA’s solution makes it possible to connect clinical trial data and secondary data sets with privacy at the forefront. Today, three large pharmaceutical companies, along with several other pharmaceutical and biotech companies of all sizes, are using Synoma to link data and conduct analyses across their drug development portfolios.

PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma | Comunicados | Edición USA

13 may 2021 PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma Pharmaceutical, biotech and other research sponsors can now connect their clinical studies to longitudinal real-world data – speeding up drug development and aligning with the 21st Century Cures Act. RALEIGH, N.C., May 13, 2021 (GLOBE NEWSWIRE) PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today an innovative tokenization solution using Synoma ®, PRA’s proprietary technology that allows for the generation of enhanced evidence for drug development. PRA’s solution makes it possible to connect clinical trial data and secondary data sets with privacy at the forefront. Today, three large pharmaceutical companies, along with several other pharmaceutical and biotech companies of all sizes, are using Synoma to link data and conduct analyses across their drug development portfolios.

PRA Health Sciences expands its response to COVID-19 with pharmacovigilance solutions for authorized vaccines and therapeutics - News Makers

PRA Health Sciences expands its response to COVID-19 with pharmacovigilance solutions for authorized vaccines and therapeutics PRA offers post-authorization safety solutions to keep up with the speed of COVID-19 vaccine and therapeutic pharmacovigilance requirements RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) PRA Health Sciences (NASDAQ: PRAH) announced today the expansion of its pharmacovigilance solution to offer full post-marketing services for authorized COVID-19 vaccines and therapeutics, including post-authorization safety studies (PASS) delivered by Real World Solutions. With more than 25 years of experience executing comprehensive pharmacovigilance and patient safety services in all key therapeutic areas including infectious diseases, PRA can work closely with drug developers and manufacturers in ensuring long-term safety and efficacy of COVID-19 vaccines and treatments.

PRA Health Sciences seleccionada por Maryland State Medical Society para ofrecer servicios de telesalud y monitoreo remoto de pacientes

PRA Health Sciences seleccionada por Maryland State Medical Society para ofrecer servicios de telesalud y monitoreo remoto de pacientes
tynmagazine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tynmagazine.com Daily Mail and Mail on Sunday newspapers.

PRA Health Sciences amplía su respuesta al COVID-19 con soluciones de farmacovigilancia para vacunas y productos terapéuticos autorizados

PRA Health Sciences amplía su respuesta al COVID-19 con soluciones de farmacovigilancia para vacunas y productos terapéuticos autorizados
tynmagazine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tynmagazine.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.